$CRBP
Corbus Pharmaceuticals Holdings Inc

2015 Q1 Form 10-K Financial Statement

#000119312515040326 Filed on February 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2013 Q4 2013
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $810.0K $290.0K $350.0K
YoY Change 1925.0% 20.69%
% of Gross Profit
Research & Development $723.4K $210.7K
YoY Change 1068.39% -60.99%
% of Gross Profit
Depreciation & Amortization $5.371K
YoY Change
% of Gross Profit
Operating Expenses $1.535M $280.0K $557.3K
YoY Change 1353.26% -32.04%
Operating Profit -$1.535M -$557.3K
YoY Change 1353.26%
Interest Expense $979.00 -$10.00K $45.11K
YoY Change -91.23% -175.19%
% of Operating Profit
Other Income/Expense, Net -$419.00 -$45.07K
YoY Change -95.95%
Pretax Income -$1.540M -$290.0K -$600.0K
YoY Change 1183.33% -32.58%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.536M -$290.0K -$602.4K
YoY Change 1224.13% -32.32%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$59.53K -$11.48K -$23.75K
COMMON SHARES
Basic Shares Outstanding 25.94M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.971M $303.0K $300.0K
YoY Change 2385.73% -40.0%
Cash & Equivalents $4.971M $303.0K $200.0K
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $200.0K $0.00 $0.00
YoY Change
Inventory
Prepaid Expenses $210.8K $2.500K
Receivables
Other Receivables
Total Short-Term Assets $5.182M $305.5K $300.0K
YoY Change 2491.11% -40.0%
LONG-TERM ASSETS
Property, Plant & Equipment $50.40K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $64.13K $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.182M $305.5K $300.0K
Total Long-Term Assets $64.13K $0.00 $0.00
Total Assets $5.246M $305.5K $300.0K
YoY Change 2523.17% -40.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $188.3K $181.5K $200.0K
YoY Change -5.85%
Accrued Expenses $294.0K $63.49K $100.0K
YoY Change 193.99% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $300.0K $300.0K
YoY Change -66.67% 50.0%
Total Short-Term Liabilities $554.8K $648.9K $600.0K
YoY Change -7.54% 100.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $300.0K $300.0K
YoY Change -100.0% -40.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $300.0K $300.0K
YoY Change -100.0% -40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $554.8K $648.9K $600.0K
Total Long-Term Liabilities $0.00 $300.0K $300.0K
Total Liabilities $554.8K $980.1K $1.000M
YoY Change -44.52% 42.86%
SHAREHOLDERS EQUITY
Retained Earnings -$5.963M -$1.887M
YoY Change
Common Stock $2.600K $696.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.692M -$1.783M -$700.0K
YoY Change
Total Liabilities & Shareholders Equity $5.246M $305.5K $300.0K
YoY Change 2523.17% -40.0%

Cashflow Statement

Concept 2015 Q1 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$1.536M -$290.0K -$602.4K
YoY Change 1224.13% -32.32%
Depreciation, Depletion And Amortization $5.371K
YoY Change
Cash From Operating Activities -$1.280M -$130.0K -$370.0K
YoY Change 814.29% -51.95%
INVESTING ACTIVITIES
Capital Expenditures $1.727K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $62.60K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 100.0K 130.0K
YoY Change -87.5%
NET CHANGE
Cash From Operating Activities -1.280M -130.0K -370.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -10.00K 100.0K 130.0K
Net Change In Cash -1.290M -30.00K -240.0K
YoY Change 821.43% -188.89%
FREE CASH FLOW
Cash From Operating Activities -$1.280M -$130.0K -$370.0K
Capital Expenditures $1.727K $0.00 $0.00
Free Cash Flow -$1.282M -$130.0K -$370.0K
YoY Change 815.52% -51.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 crbp Fair Value Of Warrant Issued
FairValueOfWarrantIssued
55000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.12
CY2009Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
27839 shares
CY2014Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0325 pure
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25941175 shares
CY2015Q1 dei Entity Public Float
EntityPublicFloat
39376913
CY2013Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
301778 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
162539 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
495016 shares
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1186989
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
542483
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6964788 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6964788 shares
CY2014Q4 us-gaap Preferred Units Offering Costs
PreferredUnitsOfferingCosts
1857668
CY2014Q4 us-gaap Cash
Cash
10974
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
709786
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
122573
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2412
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
511595
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25938332 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.83
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
33333 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.25
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.13
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
301778 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
597243 shares
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1783198
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
709786
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
648866
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
331243
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
77140
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
696
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
181471
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1886590
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63488
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-1783198
CY2013Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305520
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102696
CY2013Q4 us-gaap Notes Payable
NotesPayable
638078
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
19932
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
306835
CY2013Q4 us-gaap Liabilities
Liabilities
980109
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
303020
CY2013Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
202259
CY2013Q4 us-gaap Assets
Assets
305520
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Cash
Cash
100761
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
73206
CY2013Q4 us-gaap Assets Current
AssetsCurrent
305520
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2500
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25938332 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
167127
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
19310
CY2014Q4 us-gaap Assets Current
AssetsCurrent
6533001
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
270556
CY2014Q4 crbp Computer Hardware And Software Gross
ComputerHardwareAndSoftwareGross
17179
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6262445
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3556691 shares
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5862733
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1764338
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10405
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
738040
CY2014Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
13728
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2594
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
344160
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4427075
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
249491
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
5862733
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
140473
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
28464
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6600773
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10287214
CY2014Q4 us-gaap Notes Payable
NotesPayable
144389
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
56511
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
144389
CY2014Q4 us-gaap Liabilities
Liabilities
738040
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
55498
CY2014Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
27960
CY2014Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
6251471
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54044
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7689394
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1764338
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
13728
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1732071
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
128093
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
60373
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1408745
CY2014Q4 us-gaap Assets
Assets
6600773
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
864280
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4957 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0747 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.17
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.17
CY2014Q2 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P3Y11M19D
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6964788 shares
CY2014Q2 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.66 pure
CY2014Q2 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q2 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0125 pure
CY2014Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Reverse stock split within a range of 1:1.25 to 1:5
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
48380
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
28448
CY2014Q4 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
24293
CY2014Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
192000
CY2013Q2 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.66
CY2013Q2 crbp Additional Shares Warrants Issued Due To Anti Dilution Provision
AdditionalSharesWarrantsIssuedDueToAntiDilutionProvision
48222 shares
CY2009Q4 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.60
CY2009Q4 crbp Warrant Exercisable Term
WarrantExercisableTerm
P5Y
CY2014Q3 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
1.00
CY2014Q3 crbp Warrant Exercisable Term
WarrantExercisableTerm
P5Y
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0119 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0420 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-366715
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3395 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0509 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
105622 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2503928 shares
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6141
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-557276
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2692
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-45074
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-602350
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
754
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2013 us-gaap Interest Expense
InterestExpense
45114
CY2013 us-gaap Operating Expenses
OperatingExpenses
557276
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210670
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-239463
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1978
CY2013 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
7252
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
127252
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33478
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
0
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
41543
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
346606
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
131849
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
6141
CY2013 crbp Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-602350
CY2013 crbp Research And Development Expense Reduction
ResearchAndDevelopmentExpenseReduction
205000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M13D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.11
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
CORBUS PHARMACEUTICALS HOLDINGS, INC.
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
CRBP
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.95
CY2014 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0047 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0337 pure
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M4D
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"></td> <td valign="top" align="left"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF OPERATIONS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Business</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Corbus Pharmaceuticals Holdings, Inc. (&#x201C;CPHI&#x201D; or &#x201C;the Company&#x201D;) is a clinical stage biopharmaceutical company, focused on the development and commercialization of therapeutics to treat rare life-threating, rare inflammatory fibrotic diseases.&#xA0;Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company&#x2019;s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b>Reverse Acquisition</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> JB Therapeutics Inc. (&#x201C;JB Therapeutics&#x201D;), was incorporated on April&#xA0;24, 2009 under the laws of the State of Delaware. CPHI was incorporated on December&#xA0;18, 2013 under the laws of the State of Delaware. On April&#xA0;11, 2014, JB Therapeutics Inc. completed a reverse acquisition with CPHI. Upon the consummation of the reverse acquisition, JB Therapeutics became a wholly owned subsidiary of CPHI and changed its name to Corbus Pharmaceuticals, Inc. CPHI continues to operate the business of JB Therapeutics. All the references to the &#x201C;Company&#x201D; for activities prior to the reverse merger are to JB Therapeutics activities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> As part of the reverse acquisition, CPHI issued 9,000,000 shares of common stock to holders of JB Therapeutics common and preferred stock in exchange for a total of 5,964,649 common shares outstanding on an as converted basis. In addition, the holders of warrants to purchase common stock of JB Therapeutics received warrants, or the Replacement Warrants, to purchase 377,839 shares of CPHI common stock with an exercise price of ranging from $0.60 to $0.66. In addition, holders of JB Therapeutics Series A preferred stock received warrants to purchase 917,612 shares of common stock of CPHI. Finally, holders of outstanding options of JB Therapeutics received, in substitution for such options, options made pursuant to the Corbus 2014 Equity Incentive Plan to purchase an aggregate of 905,334 shares of CPHI common stock with exercise prices ranging from $0.11 to $0.17 per share. All share and per share amounts presented in these consolidated financial statements for the years ended December&#xA0;31, 2014 and 2013 have been retroactively restated to reflect the 1.5089 exchange ratio of JB Therapeutics shares for CPHI shares in the reverse acquisition. Immediately prior to the reverse acquisition, CPHI had 6,000,000 shares outstanding.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The reverse acquisition was accounted for as a recapitalization since the formation of CPHI was formed solely to effect the reverse acquisition and a private placement of equity and CPHI had no prior operations or net monetary assets. Thus, JB Therapeutics is deemed to be the accounting acquirer and successor entity and the historical financial statements are those of JB Therapeutics as the accounting acquirer. Following the reverse acquisition, the management of JB Therapeutics became the management of CPHI. At the date of the reverse acquisition, the 6,000,000 outstanding shares of CPHI are reflected as an issuance of common stock to the prior holders of CPHI. CPHI had no net monetary assets as of the reverse acquisition so the issuance was recorded as a reclassification between additional paid-in-capital and par value of common stock. On April&#xA0;11, 2014 and in three subsequent closings, CPHI completed a private placement of equity, raising net proceeds of approximately $8,402,000 (the &#x201C;2014 Private Placement&#x201D;) (See Note 9).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> </div>
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2361236
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0503 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3047139 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
632999 shares
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based compensation, the value of derivative instruments and the accrual of research and clinical obligations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company has granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. The Company&#x2019;s board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of preferred stock.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20159861 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4214 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0021 pure
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M12D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.95
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001595097
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1732071
CY2014 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1865046
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
193120
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4450
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-2647173
CY2014 us-gaap Interest Expense
InterestExpense
24021
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4570
CY2014 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
145006
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106688
CY2014 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
13728
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17266668 shares
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits.</p> </div>
CY2014 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
396192
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
87691 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
1108609
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
247006
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64448
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-2540485
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
2115
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
268056
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
145006
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
193120
CY2014 crbp Operating Lease Terms
OperatingLeaseTerms
P3Y
CY2014 crbp Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2540485
CY2014 crbp Forgiveness Of Debt And Accrued Interest
ForgivenessOfDebtAndAccruedInterest
7466
CY2014 crbp Conversion Of Notes Payable Accrued Interest And Accounts Payable Into Common Stock And Warrant
ConversionOfNotesPayableAccruedInterestAndAccountsPayableIntoCommonStockAndWarrant
396000
CY2014 crbp Reclassification Of Derivative Warrant Liability To Equity
ReclassificationOfDerivativeWarrantLiabilityToEquity
48380
CY2014 us-gaap Operating Expenses
OperatingExpenses
2647173
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1255535
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5959425
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
28448
CY2014 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
192000
CY2014 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8402000
CY2014 us-gaap Depreciation
Depreciation
10405
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8385109
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10305161
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
186002
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-64448
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
35550
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
29861
CY2014 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1391638
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
170239
CY2014 crbp Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2014 crbp Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Through Cashless Exercise
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsThroughCashlessExercise
21500 shares
CY2014 crbp Research And Development Expense Reduction
ResearchAndDevelopmentExpenseReduction
49000
CY2014 crbp Issuance Of Common Stock Upon Exercise Of Warrants Amount
IssuanceOfCommonStockUponExerciseOfWarrantsAmount
33333
CY2014 crbp Issuance Of Common Stock Private Placement
IssuanceOfCommonStockPrivatePlacement
8402332
CY2014 crbp Adjustments To Additional Paid In Capital Reclassification Of Warrants As Derivative Liabilities
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsAsDerivativeLiabilities
48380

Files In Submission

Name View Source Status
0001193125-15-040326-index-headers.html Edgar Link pending
0001193125-15-040326-index.html Edgar Link pending
0001193125-15-040326.txt Edgar Link pending
0001193125-15-040326-xbrl.zip Edgar Link pending
crbp-20141231.xml Edgar Link completed
crbp-20141231.xsd Edgar Link pending
crbp-20141231_cal.xml Edgar Link unprocessable
crbp-20141231_def.xml Edgar Link unprocessable
crbp-20141231_lab.xml Edgar Link unprocessable
crbp-20141231_pre.xml Edgar Link unprocessable
d854695d10k.htm Edgar Link pending
d854695dex231.htm Edgar Link pending
d854695dex311.htm Edgar Link pending
d854695dex312.htm Edgar Link pending
d854695dex321.htm Edgar Link pending
d854695dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g854695g00r23.jpg Edgar Link pending
g854695g55x45.jpg Edgar Link pending
g854695g78w36.jpg Edgar Link pending
g854695g79u12.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending